An Immunogenic Personal Neoantigen Vaccine for Melanoma Patients

Study ID Alternative Stable ID Type
phs001451 Clinical Trial

Study Description

Effective anti-tumor immunity in humans has been associated with presence of T cells targeting neoantigens that arise from non-silent tumor-specific mutations. Here we conducted whole-exome sequencing of tumor and normal cells from individual patients to identify mutations. We assessed the expression of mutated alleles by RNA-sequencing of tumor. We demonstrated the feasibility, safety and immunogenicity of a vaccine that targets up to 20 personal neoantigens predicted to be presented by the autologous patient tumor.

Archive Link Archive Accession
dbGaP phs001451

Who archives the data?

There are no publications available